Meeting
2019 ASCO Annual Meeting
Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).
Authors
Andrew B. Lassman
Columbia University Irving Medical Center, New York, NY
Andrew B. Lassman , David A. Reardon , Eudocia Quant Lee , Fabio Massaiti Iwamoto , Francisco Diaz-Mitoma , David E Anderson , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03382977
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2048)
DOI
10.1200/JCO.2019.37.15_suppl.2048
Abstract #
2048
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.
First Author: Wolfgang Wick
Poster
2014 ASCO Annual Meeting
Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
First Author: Gordana Vlahovic
Poster
2022 ASCO Annual Meeting
Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901).
First Author: Patrick Y. Wen
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
First Author: Wolfgang Wick